Astrana Health (ASTH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, at the company’s headquarters in Alhambra, CA.
Shareholders are invited to vote on key proposals, including board elections, auditor ratification, executive compensation, and an equity incentive plan.
Voting matters and shareholder proposals
Election of nine directors to serve until the 2027 annual meeting.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation program.
Approval of the Amended and Restated 2024 Equity Incentive Plan.
Proxies may vote on other business as may arise at the meeting.
Board of directors and corporate governance
Nine nominees listed for board election, including individuals with medical, business, and public sector backgrounds.
Latest events from Astrana Health
- Q2 2026 revenue up 49%, adjusted EBITDA up 43%, and net income more than doubled.ASTH
Q2 2026 - Rapid growth, tech-driven efficiencies, and resilient margins amid regulatory shifts.ASTH
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue rose 56% to $965.1M, with adjusted EBITDA up 82% and strong free cash flow growth.ASTH
Q1 2026 - Proxy covers director elections, auditor ratification, pay, equity plan, and strong governance.ASTH
Proxy filing - Record growth, resilient margins, and AI-driven efficiency amid industry headwinds.ASTH
Barclays 28th Annual Global Healthcare Conference - Q3 revenue up 37% to $478.7M; guidance raised after major acquisitions and capitation growth.ASTH
Q3 2024 - $745M deal expands reach to 1.7M members, with $12M in synergies targeted by 2027.ASTH
M&A Announcement - Q1 revenue up 53% to $620.4M, but profitability declined; 2025 outlook remains robust.ASTH
Q1 2025 - 2024 revenue rose 47% to $2.03B, with Adjusted EBITDA up 16% to $170.4M.ASTH
Q4 2024